---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: APC-004"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: APC-004. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 45 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence/apc-004"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: APC-004

<a id="heading-3.1.6"></a>

## 3.1.6 APC-004

<a id="heading-3.1.6.1"></a>

### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

#### Effect of two AD109 doses on hypoxic burden and AHI over a single night

> “We evaluated the effect of the combination (named AD109) on the sleep apnea-specific hypoxic burden (HB, primary outcome) and on AHI (secondary outcome) over a single treatment night.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.1-2"></a>

#### Rationale for testing a lower atomoxetine dose in mild to low-moderate OSA

> “In this trial, we studied patients with mild or low-moderate OSA (AHI between 5 and 20 events/h), as we hypothesized that this group of patients could be treated with a lower dose of the combination.”
> “Specifically, a lower dose of atomoxetine could help to reduce side effects and improve long-term tolerance in this population if the efficacy was comparable to the higher dose.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.1-3"></a>

#### Dose finding as described by the company

> “Prior studies indicated that doses of atomoxetine lower than 75mg were less effective in decreasing airway obstruction in OSA patients with baseline disease severity in the moderate to very severe range.”
> “We concluded that testing lower doses of atomoxetine in AD109 was most likely to be informative in patients with less severe baseline OSA.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.6.2"></a>

### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

#### Registered study dates and sites

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2020-12-22” |
| Primary completion (actual) | “2021-05-31” |
| Number of locations | “This study has 3 locations” |
| California site | “San Diego, California, United States, 92103 Pacific Research Network” |
| Georgia site | “Atlanta, Georgia, United States, 30328 NeuroTrial Research” |
| Pennsylvania site | “Philadelphia, Pennsylvania, United States, 19063 Brian Abaluck, LLC” |

Source: [ClinicalTrials.gov NCT04631107](https://clinicaltrials.gov/study/NCT04631107)

<a id="topic-3.1.6.2-2"></a>

#### Year initiated and number of sites

> “We initiated a Phase 2a trial in 2020 to perform additional dose finding for AD109, conducted at three sites in the United States.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.6.3"></a>

### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

#### Randomized, double-blind, placebo-controlled, 3-period single-dose crossover

> “This study was a randomized, double-blind, placebo-controlled, 3-period, single-dose crossover study that evaluated the safety and efficacy of 2 different dose combinations of AD109 (atomoxetine plus R-oxybutynin) in participants with mild to moderate OSA.”
> “Participants who met all enrollment criteria were centrally randomized to receive the following oral treatments prior to a single night PSG, separated by at least a 1-week washout period:”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.3-2"></a>

#### Six registered treatment sequences

> “This is a randomized, 3-period, placebo-controlled, crossover, phase 2 clinical study to examine the efficacy and safety of 2 doses of AD109 vs placebo in patients with mild obstructive sleep apnea.”
> “AD109 Dose 1- 75 mg (A), then AD109 Dose 2- 37.5 mg (B), then Placebo (C).”
> “Placebo (C), then AD109 Dose 2- 37.5 mg (B), then AD109 Dose 1- 75 mg (A)”

Source: [ClinicalTrials.gov NCT04631107](https://clinicaltrials.gov/study/NCT04631107)

<a id="topic-3.1.6.3-3"></a>

#### Standard and lower dose comparison as described by the company

> “APC-004 was a randomized, double blind, placebo-controlled, single-dose crossover trial designed to compare the clinical response and tolerability of the standard dose (aroxybutynin 2.3mg and atomoxetine 75mg) and a lower dose (aroxybutynin 2.3mg and atomoxetine 37.5mg) of AD109 to each other and to placebo in participants with baseline AHI of 5-20, a range including only mild and moderate OSA.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.6.3-4"></a>

#### Funding

> “This study was funded by Apnimed Inc.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="heading-3.1.6.4"></a>

### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

#### Inclusion: age, body mass index, AHI4 of 5 to 20 events/h, and symptoms

> “Participants had to be between 25 and 65 years of age (inclusive) at the screening visit and have a body mass index between 18.5 and 40.0 kg/m2.”
> “The screening PSG had to demonstrate an AHI (hypopneas scoring required a 4% drop in peripheral capillary oxygen saturation [SpO2]) of 5–20 events/h.”
> “Patients had to also report minimal self-reported symptomatology, such as a score ≥ 1 on the Patient Global Impression of severity (PGI-S) or history of 1 or more of the following OSA symptoms: snoring or nighttime gasping/choking, daytime sleepiness, fatigue, or decreased concentration, nonrefreshing sleep, sleep fragmentation (including from nocturia), or morning headache, irritability, decreased mood or libido.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.4-2"></a>

#### Exclusion: other sleep disorders, interacting medications, and unstable disease

> “Patients could not have another active sleep disorder or be on any medication that could affect respiratory, muscle, or neurologic function.”
> “Participants could also not have any other major organ system disease or unstable medical disorders.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.4-3"></a>

#### Exclusion: registered cardiac and CPAP criteria

> “Clinically significant cardiac disease (e.g. rhythm disturbances, coronary artery disease or heart failure or hypertension requiring more than 2 medications for control).”
> “CPAP should not be used for at least 2 weeks prior to the study”

Source: [ClinicalTrials.gov NCT04631107](https://clinicaltrials.gov/study/NCT04631107)

<a id="topic-3.1.6.4-4"></a>

#### Exclusion: insomnia, psychiatric, neurologic, constipation, and urinary retention criteria as described by the company

> “Main exclusion criteria were a history of insomnia or narcolepsy, craniofacial malformations clinically significant cardiac disease (coronary artery disease, heart failure, rhythm disturbances), psychiatric or neurologic diseases, constipation or urinary retention.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.6.5"></a>

### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

#### High-dose and low-dose AD109 and placebo at bedtime

> “Each received low-dose AD109 (37.5/2.5 mg), high-dose AD109 (75/2.5 mg), and placebo at bedtime across 3 overnight periods in a randomized order.”
> “Dosing of the study treatment occurred immediately prior to lights out.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.5-2"></a>

#### Aroxybutynin 2.5 mg with two atomoxetine doses

> “in this trial we tested the effect of aroxybutynin, a purified version of the R-enantiomer not yet commercially available, at the dose of 2.5 mg, combined with 2 doses of atomoxetine (37.5 and 75 mg) on OSA severity in a randomized, placebo-controlled, crossover trial.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="heading-3.1.6.6"></a>

### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

#### 3.1.6.6.1 Rationale for Using Hypoxic Burden as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

##### Authors' rationale: hypoxic burden as a predictor of cardiovascular morbidity and mortality

> “In this trial, we chose the sleep apnea-specific HB instead of the more traditional AHI as our primary outcome.”
> “HB has been recently introduced as a new metric to stratify OSA severity.”
> “Analysis of such studies showed that the HB is a better predictor of the cardiovascular morbidity and mortality linked to OSA compared to AHI.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.6.1-2"></a>

##### Hypoxic burden definition in the publication: all apneas and hypopneas regardless of desaturation

> “The primary objective outcome was the HB of sleep apnea, which is calculated as the area under the curve of the baseline oxygen saturation and represents the real ventilatory deficit of the disorder as it considers the frequency, length, and the depth of the obstructive events, whereas AHI simply represents the frequency of the same events.”
> “For each apnea or hypopnea (regardless of associated desaturation), the pre-event baseline saturation was defined as the maximum SpO2 during the 100 seconds prior to the end of the event and the area under this baseline value is calculated over a subject-specific search window, which was defined individually for each study, by averaging the SpO2 curve with respect to the end of all events occurring in the study.”
> “The hypoxic burden was then obtained by adding these individual desaturation areas and dividing the total area by the sleep duration, with the units of hypoxic burden being (%min)/h.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.6.1-3"></a>

##### Hypoxic burden definition in the registry: events with 4% or greater desaturation

> “Change in Hypoxic Burden (HB) is calculated as the oxygen desaturation 'area under the curve' in association with individual apneas and hypopneas.”
> “Raw measurement of HB (%min/h) is defined as the sum of individual areas (%min) divided by total sleep time (h). Events with 4% or greater desaturations were included in the calculation of HB.”

Source: [ClinicalTrials.gov NCT04631107](https://clinicaltrials.gov/study/NCT04631107)

<a id="topic-3.1.6.6.1-4"></a>

##### Primary and key secondary endpoints as described by the company

> “The primary endpoint was the reduction of HB (calculated based on AHI with four percent desaturation) and the reduction of AHI (calculated based on four percent desaturations) was a key secondary endpoint.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.6.6.1-5"></a>

##### Editorial comment on hypoxic burden as the primary endpoint

> “The primary endpoint of hypoxic burden is a laudable choice that highlights the movement away from solely relying on AHI.”
> “Further validation of this parameter is needed, but inclusion of hypoxic burden in the efficacy of new therapies is warranted and adds to the strength of the findings.”

Source: [Bierer (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713911/)

<a id="topic-3.1.6.6.1-6"></a>

##### Other outcomes: polysomnography scoring, sleepiness, and vital signs

> “Standard overnight PSGs were recorded and scored in accordance with the American Academy of Sleep Medicine scoring manual.”
> “Effects on situational, self-reported sleepiness were assessed by the Karolinska Sleepiness Scale, administered on the morning following each PSG test.”
> “On the following morning, blood pressure and heart rate were measured in the seated posture.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="heading-3.1.6.7"></a>

### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

#### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

##### Planned sample size and power

> “A total of 30 participants was planned to enter the 3-treatment crossover study.”
> “The study was planned to have 80% power to detect a treatment difference on the primary endpoint at a 2-sided 0.05 significance level, if the true difference of hypoxic burden between treatments was at least -3.7 (%min)/h.”
> “This assumed that the within-participant standard deviation was 9 and a discontinuation rate of less than 20%.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.7.1-2"></a>

##### Participants analyzed for the primary outcome in the registry

| Field | Quoted record |
| --- | --- |
| Enrollment (actual) | “Enrollment (Actual) 32” |
| Participants analyzed for the primary outcome, each comparison | “Overall Number of Participants Analyzed 27 27 27” |

Source: [ClinicalTrials.gov NCT04631107 results](https://clinicaltrials.gov/study/NCT04631107?tab=results)

<a id="heading-3.1.6.7.2"></a>

#### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

##### Safety population

> “Thirty-one participants were included in the safety population (participants who are randomized and receive at least 1 dose of any of the study treatments).”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.7.2-2"></a>

##### Statistical methods: repeated-measures model, log transformation, and three comparisons per endpoint

> “In general, continuous variables were summarized by presenting medians and interquartile ranges due to the skewed distribution of most variables.”
> “Due to the known logarithmic distribution of HB, the primary analysis of HB was performed also after log10 (HB + 1) transformation.”
> “Each endpoint for this study implicitly contained 3 hypothesis tests based on comparisons between study treatments: (1) 75/2.5 dose vs placebo, (2) 37.5/2.5 dose vs placebo, (3) 37.5/2.5 dose vs 75/2.5 dose.”
> “A repeated-measures model was used to compare log10(HB+ 1), HB (without log-transformation), AHI, and other PSG variables between treatment arms.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.7.2-3"></a>

##### Safety analysis methods

> “The analyses were descriptive and were based on the safety set.”
> “The safety assessments were summarized by the study treatment the participant received within each period.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="heading-3.1.6.8"></a>

### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

#### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

##### Screening, randomization, completion, and withdrawals

> “A total of 65 participants signed the informed consent form and were enrolled in the study.”
> “Thirty-three participants failed screening and 32 participants were randomized (Figure 1).”
> “One ineligible participant was inadvertently randomized but not treated.”
> “Four participants were treated but terminated before completing the study.”
> “Three patients withdrew for personal reasons and one for an adverse event (severe oxygen desaturation during sleep), which raised the safety risk according to one of the study investigators.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.8.1-2"></a>

##### Registry participant flow

> “A total of 65 participants were screened in the study. Thirty-two participants were randomized.”
> “Twenty-seven participants completed the study. Four participants were treated but early terminated from the study.”

Source: [ClinicalTrials.gov NCT04631107 results](https://clinicaltrials.gov/study/NCT04631107?tab=results)

<a id="topic-3.1.6.8.1-3"></a>

##### Completion as reported by the company

> “Thirty-two participants were randomized, and 27 (84%) completed the trial.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.6.8.2"></a>

#### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

##### Demographics of the safety population

> “Patient median (interquartile range) age was 53 years (47 to 62) and body mass index was 30.4 kg/m2 (27.0 to 33.1).”
> “There were 11 female patients (35.5% of the total) and participants were mostly white (71%) and African American (23%), with the remaining patients (n = 2) having multiple ethnicities.”
> “Twenty-five (80.6%) participants were not Hispanic or Latino.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.8.2-2"></a>

##### Baseline polysomnography, median (interquartile range), AHI and ODI with 4% desaturation criterion

| Parameter | Baseline (n = 31) |
| --- | --- |
| Log10 (HB + 1) | “1.11 (0.76–1.32)” |
| HB, (%min)/h | “11.8 (4.8 to 20.0)” |
| AHI, events/h | “13.5 (8.1 to 17.0)” |
| AHI supine, events/h | “18.6 (11.3 to 29.1)” |
| ODI 4%, events/h | “10.0 (6.0 to 15.4)” |

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.8.2-3"></a>

##### Registry baseline hypoxic burden, median (full range)

| Field | Quoted record |
| --- | --- |
| Hypoxic burden, (%*min)/hour | “11.8 (2.08 to 87.78)” |
| Measure description | “Hypoxic burden is a measure of the overall burden of de-oxygenation (hypoxia) due to upper airway obstructive events for every hour of sleep, measured from the SaO2 signal on the polysomnography done overnight.” |

Source: [ClinicalTrials.gov NCT04631107 results](https://clinicaltrials.gov/study/NCT04631107?tab=results)

<a id="heading-3.1.6.8.3"></a>

#### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

##### Hypoxic burden and AHI4 on a single night: high and low dose versus placebo

> “Median [interquartile range] hypoxic burden for participants on placebo was 13.9[4.5–21.9] (%min)/h vs 2.3[0.1–10.5] (%min)/h for patients on the high dose (P < .001) and to 7.3[2–12.5] (%min)/h on the low dose (P < .01).”
> “Apnea-hypopnea index went from a median of 13.2[8.0–19.1] events/h on placebo reduced to 5.5[2.2 to 9.6] events/h on the high dose (P < .001) and to 7.8[4–13.7] events/h on the low dose (P < .05).”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.8.3-2"></a>

##### Respiratory polysomnography parameters by treatment, median (interquartile range), AHI and ODI with 4% desaturation criterion

| Parameter | Placebo (n = 29) | AD109 low dose (n = 28) | AD109 high dose (n = 30) |
| --- | --- | --- | --- |
| Log10 (HB + 1) | “1.17 (0.74–1.36)” | “0.92 (0.47–1.13)” | “0.51 (0.05–1.06)” |
| HB, (%min)/h | “13.9 (4.5 to 21.9)” | “7.3 (2.0 to 12.5)” | “2.3 (0.1 to 10.5)” |
| AHI, events/h | “13.2 (8.0 to19.1)” | “7.8 (4.0 to 13.7)” | “5.5 (2.2 to 9.6)” |
| AHI supine, events/h | “19.8 (13.2 to 29.7)” | “12.4 (8.1 to 25.0)” | “9.2 (4.4 to 15.7)” |
| AHI NREM, events/h | “7.9 (4.0 to 13.0)” | “7.2 (3.0 to 12.3)” | “3.5 (1.7 to 7)” |
| ODI 4%, events/h | “11.1 (4.5 to 15.6)” | “7.1 (4.2 to 13.4)” | “6.4 (1.4 to 10.8)” |

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.8.3-3"></a>

##### Dose response and hypoxic burden responders

> “AHI and Log10(HB + 1) were also significantly improved on AD109 high dose compared to low dose, suggesting a dose-related effect size.”
> “Note that > 70% of patients had a reduction of at least 30% in HB and > 40% of participants had a reduction in HB > 90% on high-dose AD109.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.8.3-4"></a>

##### AHI4 by body position and sleep stage

> “The effect on the AHI was maintained when analysis was limited to the supine position and was present in both non-rapid eye movement and rapid eye movement (REM) sleep, although the reduction in AHI did not reach statistical significance in REM (P = .12 on high dose vs placebo) probably because only 13 participants had REM on both placebo and high dose AD109, and thus the analysis lacked of statistical power.”
> “There was no relationship between the reduction in REM sleep and the reduction in overall AHI for both the low dose (P = .12, r2 = 0.11) or the high dose of AD109 (P = .56, r2 = 0.01).”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.8.3-5"></a>

##### Registry primary outcome: mean difference in hypoxic burden (95% confidence interval), events with 4% or greater desaturation

| Comparison | Log10 HB, difference in log10HB[(%*min)/h] | Raw HB, (%*min)/h |
| --- | --- | --- |
| AD109 dose 1 (atomoxetine 75 mg) vs placebo | “-0.40 (-0.54 to -0.25)” | “-6.90 (-10.20 to -3.60)” |
| AD109 dose 2 (atomoxetine 37.5 mg) vs placebo | “-0.21 (-0.36 to -0.07)” | “-4.70 (-8.01 to -1.38)” |
| Dose 2 vs dose 1 | “0.18 (0.04 to 0.33)” | “2.20 (-1.23 to 5.36)” |

Source: [ClinicalTrials.gov NCT04631107 results](https://clinicaltrials.gov/study/NCT04631107?tab=results)

<a id="topic-3.1.6.8.3-6"></a>

##### Percentage reductions in hypoxic burden and AHI4 versus placebo, as reported in the company prospectus

> “Standard dose AD109 significantly reduced HB by 84% (p<0.0001) and AHI by 59% (p<0.0001) relative to placebo.”
> “Low dose also significantly reduced HB by 47% (p=0.0048) and AHI by 41% (p<0.05) vs placebo.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.6.8.4"></a>

#### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.6.8.4-1"></a>

##### Karolinska Sleepiness Scale the morning after dosing

> “Subjectively, the proportion of nonsleepy patients, defined by a Karolinska Sleepiness Scale < 5, was 0.83 (95% confidence interval 0.69 to 0.97) on placebo, 0.93 (0.83 to 1.00) on low-dose AD109, and 0.86 (0.74 to 0.99) on high-dose AD109.”
> “These different outcomes between treatments were not statistically significant.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="heading-3.1.6.8.5"></a>

#### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

##### Treatment-emergent adverse events in at least 2 participants, safety population

| System organ class (preferred term) | High dose (n = 30) | Low dose (n = 28) | Placebo (n = 29) | Overall (n = 31) |
| --- | --- | --- | --- | --- |
| All body systems | “7 (23.3%)” | “6 (21.4%)” | “7 (24.1%)” | “13 (41.9%)” |
| Gastrointestinal disorders (dry mouth) | “2 (6.7%)” | “1 (3.6%)” | “0” | “3 (9.7%)” |
| Metabolism and nutrition disorders (decreased appetite) | “2 (6.7%)” | “0” | “0” | “2 (6.5%)” |
| General disorders and administration site (thirst) | “0” | “1 (3.6%)” | “2 (6.9%)” | “2 (6.5%)” |

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.8.5-2"></a>

##### Most frequent adverse events and authors' safety assessment

> “The most frequently reported treatment emergent adverse effects occurring in at least 2 study participants were dry mouth (3 [9.7%] participants), decreased appetite (2 [6.5%] participants), and thirst (2 [6.5%] participants).”
> “Both high-dose AD109 and low-dose AD109 were safe and well-tolerated, without clear difference between the high and low doses or between the active doses and placebo.”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.8.5-3"></a>

##### Registry adverse events: deaths, serious adverse events, and other adverse events at a 5% threshold

| Event | AD109 dose 1 (75 mg) | AD109 dose 2 (37.5 mg) | Placebo |
| --- | --- | --- | --- |
| All-cause mortality | “0/30 (0.00%)” | “0/28 (0.00%)” | “0/29 (0.00%)” |
| Other adverse events, total | “4/30 (13.33%)” | “2/28 (7.14%)” | “2/29 (6.90%)” |
| Dry mouth | “2/30 (6.67%)” | “1/28 (3.57%)” | “0/29 (0.00%)” |
| Decreased appetite | “2/30 (6.67%)” | “0/28 (0.00%)” | “0/29 (0.00%)” |

Source: [ClinicalTrials.gov NCT04631107 results](https://clinicaltrials.gov/study/NCT04631107?tab=results)

<a id="topic-3.1.6.8.5-4"></a>

##### Sleep architecture and arousals

> “As shown in Table 2, a high dose of AD109 reduced total sleep time and sleep efficiency and increased wake after sleep onset compared to placebo.”
> “In addition, both doses reduced REM sleep and increased N1.”
> “The high dose of AD109 reduced the respiratory arousals, but both doses increased the number of spontaneous arousals (ie, not associated with respiratory events or leg movements), so that the total number of arousals was increased on AD109 (P < .05).”

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="topic-3.1.6.8.5-5"></a>

##### Sleep and morning vital signs by treatment, median (interquartile range)

| Parameter | Placebo | Low dose | High dose |
| --- | --- | --- | --- |
| Total sleep time (min) | “406 (372 to 430)” | “378 (333 to 408)” | “361 (325 to 392)” |
| Wake after sleep onset (min) | “61.0 (45.0 to 97.5)” | “94.5 (65.5 to 127.3)” | “108.0 (77.5 to 148.0)” |
| Stage REM (%TST) | “19.3 (16.6 to 23.1)” | “4.0 (0.0 to 8.1)” | “1.3 (0.0 to 3.7)” |
| Heart rate (beats per minute) | “75.0 (65.0 to 82.0)” | “76.5 (64.5 to 86.0)” | “74.00 (64.0 to 82.0)” |
| Systolic blood pressure (mm Hg) | “127.0 (118.0 to 137.0)” | “127.5 (119.0 to 135.5)” | “124.0 (120.0 to 135.0)” |
| Diastolic blood pressure (mm Hg) | “78.0 (71.0 to 83.0)” | “78.5 (72.0 to 86.0)” | “77.0 (68.0 to 83.0)” |

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/)

<a id="heading-3.1.6.9"></a>

### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

#### Summary

- Design: single-dose crossover with one night of polysomnography per treatment, separated by washouts of at least 1 week.
- Population: AHI4 of 5 to 20 events/h, ages 25 to 65, and BMI 18.5 to 40.0 kg/m2, with exclusion of other active sleep disorders, medications affecting respiratory, muscle, or neurologic function, and unstable medical disorders (the prospectus names a history of insomnia). The registry describes the population as mild obstructive sleep apnea, and the publication as mild or low-moderate OSA.
- Size: 32 participants were randomized, 31 were treated, and 27 were analyzed for each primary comparison in the registry.
- Hypoxic burden definition differs by source: the publication includes each apnea or hypopnea regardless of associated desaturation, and the registry includes events with 4% or greater desaturation. An accompanying editorial states that further validation of the measure is needed.
- REM analysis: only 13 participants had REM sleep on both placebo and high-dose AD109, which the authors state left the REM analysis without statistical power.
- Funding: the publication states the study was funded by Apnimed.

Source: [Rosenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713910/); [ClinicalTrials.gov NCT04631107](https://clinicaltrials.gov/study/NCT04631107); [ClinicalTrials.gov NCT04631107 results](https://clinicaltrials.gov/study/NCT04631107?tab=results); [Bierer (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713911/); [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
